PT - JOURNAL ARTICLE AU - Yeker, Richard M AU - Pinal-Fernandez, Iago AU - Kishi, Takayuki AU - Pak, Katherine AU - Targoff, Ira N AU - Miller, Frederick W AU - Rider, Lisa G AU - Mammen, Andrew L ED - , TI - Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis AID - 10.1136/annrheumdis-2017-212436 DP - 2018 May 01 TA - Annals of the Rheumatic Diseases PG - 714--719 VI - 77 IP - 5 4099 - http://ard.bmj.com/content/77/5/714.short 4100 - http://ard.bmj.com/content/77/5/714.full SO - Ann Rheum Dis2018 May 01; 77 AB - Objectives Autoantibodies recognising cytosolic 5′-nucleotidase 1A (NT5C1A) are found in adult patients with myositis and other autoimmune diseases. They are especially prevalent in adults with inclusion body myositis (IBM), in which they are associated with more severe weakness and higher mortality. This study was undertaken to define the prevalence and clinical features associated with anti-NT5C1A autoantibodies in juvenile myositis.Methods We screened sera from 380 patients with juvenile myositis, 30 patients with juvenile idiopathic arthritis (JIA) and 92 healthy control children for anti-NT5C1A autoantibodies. Clinical characteristics were compared between patients with myositis with and without anti-NT5C1A autoantibodies.Results Anti-NT5C1A autoantibodies were present in 102 of 380 (27%) patients with juvenile myositis and in 11 of 92 (12%) healthy control children (P=0.002) and 27% of children with JIA (P=0.05 vs controls). Sera of 83 of 307 (27%) patients with juvenile dermatomyositis and 16 of 46 (35%) patients with juvenile overlap myositis were anti-NT5C1A autoantibody-positive (P<0.01 vs healthy controls for each), but sera of only 3 of 27 (11%) patients with juvenile polymyositis were anti-NT5C1A-positive. Patients with juvenile myositis with and without anti-NT5C1A autoantibodies had similar clinical phenotypes. However, patients with anti-NT5C1A autoantibody-positive myositis had greater pulmonary symptoms at diagnosis (P=0.005), more frequent hospitalisations (P=0.01) and required a larger number of medications (P<0.001).Conclusion Anti-NT5C1A autoantibodies are present in more than one-quarter of children with juvenile myositis and JIA compared with only 12% of healthy children, suggesting they are myositis-associated in children. As in adults with IBM, patients with juvenile myositis with anti-NT5C1A autoantibodies have more severe disease.